Wanbury Ltd
WANBURYWanbury Ltd
WANBURY
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 18.96 | 35.94 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Wanbury Limited is a pharmaceutical company which offers active pharmaceutical ingredient in over 70 countries.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 424.66 | 523.49 | 447.80 | 400.70 | 451.23 | 394.92 | 589.07 | 500.56 | 604.20 | 606.95 | ||||||||||
Raw Materials | 182.15 | 191.12 | 166.40 | 201.26 | 169.75 | 228.53 | 325.07 | 274.31 | 306.52 | 506.90 | ||||||||||
| Power & Fuel Cost | 18.51 | 18.74 | 15.26 | 14.46 | 15.38 | 17.13 | 18.41 | 20.59 | 24.58 | |||||||||||
| Employee Cost | 85.59 | 87.77 | 87.32 | 75.89 | 67.48 | 64.15 | 74.81 | 81.00 | 86.92 | |||||||||||
| Selling & Administrative Expenses | 70.43 | 76.62 | 64.45 | 63.70 | 55.36 | 45.49 | 55.13 | 59.28 | 76.53 | |||||||||||
| Operating & Other expenses | 34.22 | 41.03 | 105.59 | 20.52 | 36.04 | 19.20 | 2.44 | 41.89 | 11.10 | |||||||||||
EBITDA | 33.76 | 108.21 | 8.78 | 24.87 | 107.22 | 20.42 | 113.21 | 23.49 | 98.55 | 100.05 | ||||||||||
| Depreciation/Amortization | 9.05 | 10.32 | 10.30 | 9.97 | 9.68 | 9.75 | 11.45 | 12.38 | 13.03 | 13.21 | ||||||||||
| PBIT | 24.71 | 97.89 | -1.52 | 14.90 | 97.54 | 10.67 | 101.76 | 11.11 | 85.52 | 86.84 | ||||||||||
| Interest & Other Items | 31.87 | 35.51 | 30.86 | 39.88 | 32.87 | 23.07 | 20.61 | 21.39 | 29.18 | 33.46 | ||||||||||
| PBT | -7.16 | 62.38 | -32.38 | -24.98 | 64.67 | -12.40 | 81.15 | -10.28 | 56.34 | 53.38 | ||||||||||
| Taxes & Other Items | 0.00 | 0.39 | -0.38 | -0.14 | 0.21 | 0.20 | -0.35 | 0.11 | 0.38 | 0.40 | ||||||||||
| Net Income | -7.16 | 61.99 | -32.00 | -24.84 | 64.46 | -12.60 | 81.50 | -10.39 | 55.96 | 52.98 | ||||||||||
| EPS | -3.59 | 28.71 | -13.63 | -10.47 | 26.46 | -5.04 | 28.26 | -3.18 | 17.10 | 16.18 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Wanbury Ltd | 17.95 | 35.94 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare WANBURY with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.22%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
WANBURY has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 29, 2010
Dividend/Share
₹1.00
Ex DateEx Date
Jul 29, 2010
Wanbury will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Wanbury announced that the 36th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net profit of Wanbury declined 77.83% to Rs 1.04 crore in the quarter ended June 2024 as against Rs 4.69 crore during the previous quarter ended June 2023. Sales declined 10.38% to Rs 131.11 crore in the quarter ended June 2024 as against Rs 146.29 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales131.11146.29 -10 OPM %8.379.12 - PBDT4.338.18 -47 PBT1.044.99 -79 NP1.044.69 -78 Powered by Capital Market - Live
Wanbury will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Wanbury surges 5% after USFDA issues Zero observations for Patalganga site
Wanbury Consolidated June 2023 Net Sales at Rs 146.29 crore, up 25.09% Y-o-Y
Stocks In Focus: Adani, Indian Hotels, Lupin, Kalpataru, in news Today
Wanbury Consolidated September 2022 Net Sales at Rs 123.96 crore, down 0.11% Y-o-Y
Wanbury Standalone September 2022 Net Sales at Rs 123.96 crore, down 0.11% Y-o-Y
Wanbury reports consolidated net profit of Rs 82.54 crore in the March 2022 quarter
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.56%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.18% to 0.16%